EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19
Research in the development of new therapeutic agents with a wide spectrum of the antiviral activity and a low ability to develop resistance remains the main dimension in combating the global threat to public health. The need for a parenteral form of favipiravir was dictated by the necessity to incr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2022-03-01
|
| Series: | Фармация и фармакология (Пятигорск) |
| Subjects: | |
| Online Access: | https://www.pharmpharm.ru/jour/article/view/1034 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849690553467273216 |
|---|---|
| author | L. A. Balykova K. Ya. Zaslavskaya V. F. Pavelkina N. A. Pyataev N. M. Selezneva N. V. Kirichenko A. Yu. Ivanova G. V. Rodoman K. B. Kolontarev K. S. Skrupsky E. N. Simakina O. A. Mubarakshina A. V. Taganov D. Yu. Pushkar |
| author_facet | L. A. Balykova K. Ya. Zaslavskaya V. F. Pavelkina N. A. Pyataev N. M. Selezneva N. V. Kirichenko A. Yu. Ivanova G. V. Rodoman K. B. Kolontarev K. S. Skrupsky E. N. Simakina O. A. Mubarakshina A. V. Taganov D. Yu. Pushkar |
| author_sort | L. A. Balykova |
| collection | DOAJ |
| description | Research in the development of new therapeutic agents with a wide spectrum of the antiviral activity and a low ability to develop resistance remains the main dimension in combating the global threat to public health. The need for a parenteral form of favipiravir was dictated by the necessity to increase the efficacy of therapy in COVID-19 inpatients. This dosage form has expanded the possibilities of drug therapy in the inpatients, for whom a therapeutic effect acceleration and a high safety profile of the drugs used are especially important.The aim of the article is the evaluation of the efficacy and safety of a medicinal product containing favipiravir for the parenteral administration against the background of pathogenetic and symptomatic therapy, in comparison with standard therapy in hospitalized COVID-19 patients.Materials and methods. An open, randomized, multicenter comparative study was conducted in 6 research centers in the Russian Federation to evaluate the efficacy and safety of favipiravir, a lyophilisate for the preparation of a concentrate for the infusion solution administrated to the patients hospitalized with COVID-19. Screening procedures and randomization were completed in 217 patients, 209 of which had completed the study in accordance with the protocol.Results. Between the study groups, statistically significant differences have been found out, making it possible to consider the hypothesis of the drug Areplivir (favipiravir) superiority for the parenteral administration over the standard therapy, which included favipiravir (p. o.) and remdesivir. A comparative analysis has shown that a course of therapy with the parenteral favipiravir drug leads to a significant improvement in the condition of patients with COVID-19, significant benefits in terms of the speed and frequency of improvement in the clinical status of patients, as well as a reduction in the hospital stay length. It has been proven that therapy with a drug containing favipiravir for the parenteral administration does not adversely affect the parameters of clinical and biochemical blood tests, urinalysis, coagulograms, vital signs and ECG, which indicates the therapy safety. The study drug is characterized by a high safety profile and tolerability.Conclusion. The versatility and resistance to mutations of RNA-dependent RNA polymerase make it possible to consider it as the main target for combating the most common RNA viruses that cause ARVI, that determines the need further studies of favipiravir to expand the range of its indications. |
| format | Article |
| id | doaj-art-42515d823ea7456c9eabf432ecec4a2e |
| institution | DOAJ |
| issn | 2307-9266 2413-2241 |
| language | Russian |
| publishDate | 2022-03-01 |
| publisher | Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute |
| record_format | Article |
| series | Фармация и фармакология (Пятигорск) |
| spelling | doaj-art-42515d823ea7456c9eabf432ecec4a2e2025-08-20T03:21:16ZrusVolgograd State Medical University, Pyatigorsk Medical and Pharmaceutical InstituteФармация и фармакология (Пятигорск)2307-92662413-22412022-03-0110111312610.19163/2307-9266-2022-10-1-113-126428EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19L. A. Balykova0K. Ya. Zaslavskaya1V. F. Pavelkina2N. A. Pyataev3N. M. Selezneva4N. V. Kirichenko5A. Yu. Ivanova6G. V. Rodoman7K. B. Kolontarev8K. S. Skrupsky9E. N. Simakina10O. A. Mubarakshina11A. V. Taganov12D. Yu. Pushkar13National Research Ogarev Mordovia State UniversityLimited Liability Company “Promomed RUS”National Research Ogarev Mordovia State UniversityNational Research Ogarev Mordovia State UniversityNational Research Ogarev Mordovia State UniversityIvanovo Clinical Hospital named after the KuvaevsRegional Clinical Hospital; Ryazan State Medical University named after academician I.P. PavlovMunicipal clinical hospital No. 24, Moscow City Health DepartmentMoscow State Medical and Dental University named after A.I. Evdokimov; City Clinical Hospital named after S.I. Spasokukotsky, Moscow City Health DepartmentCity Clinical Hospital named after S.I. Spasokukotsky, Moscow City Health DepartmentSmolensk clinical hospital No.1; Smolensk State Medical UniversityVoronezh State Medical University named after N.N. BurdenkoPeoples’ Friendship UniversityMoscow State Medical and Dental University named after A.I. Evdokimov; City Clinical Hospital named after S.I. Spasokukotsky, Moscow City Health DepartmentResearch in the development of new therapeutic agents with a wide spectrum of the antiviral activity and a low ability to develop resistance remains the main dimension in combating the global threat to public health. The need for a parenteral form of favipiravir was dictated by the necessity to increase the efficacy of therapy in COVID-19 inpatients. This dosage form has expanded the possibilities of drug therapy in the inpatients, for whom a therapeutic effect acceleration and a high safety profile of the drugs used are especially important.The aim of the article is the evaluation of the efficacy and safety of a medicinal product containing favipiravir for the parenteral administration against the background of pathogenetic and symptomatic therapy, in comparison with standard therapy in hospitalized COVID-19 patients.Materials and methods. An open, randomized, multicenter comparative study was conducted in 6 research centers in the Russian Federation to evaluate the efficacy and safety of favipiravir, a lyophilisate for the preparation of a concentrate for the infusion solution administrated to the patients hospitalized with COVID-19. Screening procedures and randomization were completed in 217 patients, 209 of which had completed the study in accordance with the protocol.Results. Between the study groups, statistically significant differences have been found out, making it possible to consider the hypothesis of the drug Areplivir (favipiravir) superiority for the parenteral administration over the standard therapy, which included favipiravir (p. o.) and remdesivir. A comparative analysis has shown that a course of therapy with the parenteral favipiravir drug leads to a significant improvement in the condition of patients with COVID-19, significant benefits in terms of the speed and frequency of improvement in the clinical status of patients, as well as a reduction in the hospital stay length. It has been proven that therapy with a drug containing favipiravir for the parenteral administration does not adversely affect the parameters of clinical and biochemical blood tests, urinalysis, coagulograms, vital signs and ECG, which indicates the therapy safety. The study drug is characterized by a high safety profile and tolerability.Conclusion. The versatility and resistance to mutations of RNA-dependent RNA polymerase make it possible to consider it as the main target for combating the most common RNA viruses that cause ARVI, that determines the need further studies of favipiravir to expand the range of its indications.https://www.pharmpharm.ru/jour/article/view/1034favipiravircovid-19sars-cov-2novel coronavirus infectionareplivir |
| spellingShingle | L. A. Balykova K. Ya. Zaslavskaya V. F. Pavelkina N. A. Pyataev N. M. Selezneva N. V. Kirichenko A. Yu. Ivanova G. V. Rodoman K. B. Kolontarev K. S. Skrupsky E. N. Simakina O. A. Mubarakshina A. V. Taganov D. Yu. Pushkar EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19 Фармация и фармакология (Пятигорск) favipiravir covid-19 sars-cov-2 novel coronavirus infection areplivir |
| title | EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19 |
| title_full | EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19 |
| title_fullStr | EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19 |
| title_full_unstemmed | EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19 |
| title_short | EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19 |
| title_sort | effectiveness and safety of favipiravir infusion in patients hospitalized with covid 19 |
| topic | favipiravir covid-19 sars-cov-2 novel coronavirus infection areplivir |
| url | https://www.pharmpharm.ru/jour/article/view/1034 |
| work_keys_str_mv | AT labalykova effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT kyazaslavskaya effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT vfpavelkina effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT napyataev effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT nmselezneva effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT nvkirichenko effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT ayuivanova effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT gvrodoman effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT kbkolontarev effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT ksskrupsky effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT ensimakina effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT oamubarakshina effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT avtaganov effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 AT dyupushkar effectivenessandsafetyoffavipiravirinfusioninpatientshospitalizedwithcovid19 |